RecruitingPhase 2NCT06358638

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

Studying Sickle cell disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Children's National Research Institute
Principal Investigator
Robert Nickel, MD, MD, MPH
Children's National Research Institute
Intervention
Daratumumab(drug)
Enrollment
12 enrolled
Eligibility
2-25 years · All sexes
Timeline
2024 – 2054

Study locations (1)

Collaborators

Alberta Children's Hospital · The Hospital for Sick Children · Levine Children's Hospital · Ann & Robert H Lurie Children's Hospital of Chicago · Nationwide Children's Hospital · Children's Hospital at Montefiore · Doris Duke Charitable Foundation · Janssen Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06358638 on ClinicalTrials.gov

Other trials for Sickle cell disease

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell disease →

← Back to all trials